TIDMIMM
RNS Number : 6189J
Immupharma PLC
24 August 2021
24 August 2021
ImmuPharma PLC
("ImmuPharma" or the "Company")
Director & PDMR Share Purchases
ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the
specialist drug discovery and development company, announces that
each member of the Board of Directors and PDMR, Ewa Flynn (Chief
Financial Officer) have on 23 & 24 August 2021 purchased in
total 670,000 ordinary shares of 10p in the Company ("Ordinary
Shares").
Details of the share purchases by the Board and their current
interests in shares following the transactions are set out
below.
NAME & TITLE ORDINARY SHARES NUMBER OF ORDINARY % OF ISSUED SHARE
PURCHASED SHARES HELD POST CAPITAL
& PURCHASE PRICE TRANSACTION
Tim McCarthy
Chairman & Chief
Executive Officer 250,000 @ 8.26p 288,462 0.12%
------------------ ------------------- ------------------
Dr Tim Franklin
Chief Operating
Officer 125,000 @ 7.99p 125,000 0.05%
------------------ ------------------- ------------------
Dr Sanjeev Pandya
Senior Non-Executive
Director 125,000 @ 8.00p 125,000 0.05%
------------------ ------------------- ------------------
Lisa Baderoon
Non-Executive
Director & Head
of Investor Relations 140,000 @ 8.1957p 183,963 0.07%
------------------ ------------------- ------------------
Ewa Flynn
Chief Financial
Officer &
Company Secretary 30,000 @ 7.892p 30,000 0.01%
------------------ ------------------- ------------------
Full disclosure of the transactions by persons discharging
managerial responsibilities and persons closely associated with
them ("PDMR's") are detailed at the end of the announcement.
End
This announcement contains inside information as stipulated
under the UK version of the Market Abuse Regulation no 596/2014
which is part of English law by virtue of the European (withdrawal)
Act 2018, as amended. on publication of this announcement via a
regulatory information service, this information is considered to
be in the public domain.
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chairman and Chief Executive
Officer + 44 (0) 207 152 4080
Dr Tim Franklin, Chief Operating Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 36 8 3550
Stanford Capital Partners (Joint Broker)
Patrick Claridge +44 (0) 203 815 8880
John Howes
Bob Pountney
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
4Reliance (Euronext Growth Listing Sponsor) +32 (0) 2 747 02 60
Jean-Charles Snoy
Degroof Petercam (Liquidity Provider) +32 (0) 2 287 95 34
Erik De Clippel
Backstage Communication
Olivier Duquaine +32 (0) 477 504 784
Gunther De Backer +32 (0) 475 903 909
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases, metabolic diseases,
anti-infectives and cancer. The lead program, Lupuzor(TM), is a
first-in class autophagy immunomodulator which is in Phase 3 for
the treatment of lupus and preclinical analysis suggest therapeutic
activity for many other autoimmune diseases that share the same
autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals
signed on 28 November 2019, an exclusive licence and development
agreement and trademark agreement for Lupuzor(TM) to fund a new
international Phase 3 trial for Lupuzor(TM) and commercialise in
the US.
For additional information about ImmuPharma please visit
www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code:
213800VZKGHXC7VUS895.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
The information set out below is provided in accordance with the
requirements of Article 19(3) of the EU Market Abuse Regulation No
596/2014.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Tim McCarthy
------------------------------------------ -------------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------------------
a) Position / status Chairman and Chief Executive Officer
------------------------------------------ -------------------------------------------
b) Initial notification Initial notification
/ Amendment
------------------------------------------ -------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------------------
a) Name ImmuPharma PLC
------------------------------------------ -------------------------------------------
b) LEI 213800VZKGHXC7VUS895
------------------------------------------ -------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
---------------------------------------------------------------------------------------
a) Description of the Ordinary Shares of 10p each
financial instrument
, type of instrument
ISIN: GB0033711010
Identification code
------------------------------------------ -------------------------------------------
b) Nature of the transaction On-market purchase
------------------------------------------ -------------------------------------------
c) Price(s) and volume(s) Price Volume
------------------------------------------ ------------------ -----------------------
8.26p 250,000
----------------------------------------------- ------------------ -----------------------
d) Aggregated information
- Aggregated volume
- Price
------------------------------------------ -------------------------------------------
e) Date of the transaction 23 August 2021
------------------------------------------ -------------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market (XLON)
------------------------------------------ -------------------------------------------
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
The information set out below is provided in accordance with the
requirements of Article 19(3) of the EU Market Abuse Regulation No
596/2014.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr Tim Franklin
------------------------------------------ -------------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------------------
a) Position / status Chief Operating Officer
------------------------------------------ -------------------------------------------
b) Initial notification Initial notification
/ Amendment
------------------------------------------ -------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------------------
a) Name ImmuPharma PLC
------------------------------------------ -------------------------------------------
b) LEI 213800VZKGHXC7VUS895
------------------------------------------ -------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
---------------------------------------------------------------------------------------
a) Description of the Ordinary Shares of 10p each
financial instrument
, type of instrument
ISIN: GB0033711010
Identification code
------------------------------------------ -------------------------------------------
b) Nature of the transaction On-market purchase
------------------------------------------ -------------------------------------------
c) Price(s) and volume(s) Price Volume
------------------------------------------ ------------------ -----------------------
7.99p 125,000
----------------------------------------------- ------------------ -----------------------
d) Aggregated information
- Aggregated volume
- Price
------------------------------------------ -------------------------------------------
e) Date of the transaction 24 August 2021
------------------------------------------ -------------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market (XLON)
------------------------------------------ -------------------------------------------
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
The information set out below is provided in accordance with the
requirements of Article 19(3) of the EU Market Abuse Regulation No
596/2014.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr Sanjeev Pandya
------------------------------------------ -------------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------------------
a) Position / status Senior Non-Executive Director
------------------------------------------ -------------------------------------------
b) Initial notification Initial notification
/ Amendment
------------------------------------------ -------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------------------
a) Name ImmuPharma PLC
------------------------------------------ -------------------------------------------
b) LEI 213800VZKGHXC7VUS895
------------------------------------------ -------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
---------------------------------------------------------------------------------------
a) Description of the Ordinary Shares of 10p each
financial instrument
, type of instrument
ISIN: GB0033711010
Identification code
------------------------------------------ -------------------------------------------
b) Nature of the transaction On-market purchase
------------------------------------------ -------------------------------------------
c) Price(s) and volume(s) Price Volume
------------------------------------------ ------------------ -----------------------
8p 125,000
----------------------------------------------- ------------------ -----------------------
d) Aggregated information
- Aggregated volume
- Price
------------------------------------------ -------------------------------------------
e) Date of the transaction 23 August 2021
------------------------------------------ -------------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market (XLON)
------------------------------------------ -------------------------------------------
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
The information set out below is provided in accordance with the
requirements of Article 19(3) of the EU Market Abuse Regulation No
596/2014.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Lisa Baderoon
---------------------------------------- --------------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------------------
a) Position / status Non-Executive Director & Head of Investor
Relations
---------------------------------------- --------------------------------------------
b) Initial notification Initial notification
/ Amendment
---------------------------------------- --------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------------
a) Name ImmuPharma PLC
---------------------------------------- --------------------------------------------
b) LEI 213800VZKGHXC7VUS895
---------------------------------------- --------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
--------------------------------------------------------------------------------------
a) Description of the Ordinary Shares of 10p each
financial instrument
, type of instrument
ISIN: GB0033711010
Identification code
---------------------------------------- --------------------------------------------
b) Nature of the transaction On-market purchase
---------------------------------------- --------------------------------------------
c) Price(s) and volume(s) Price Volume
---------------------------------------- ---------------------- --------------------
8.1957p 140,000
--------------------------------------------- ---------------------- --------------------
d) Aggregated information
- Aggregated volume
- Price
---------------------------------------- --------------------------------------------
e) Date of the transaction 23 August 2021
---------------------------------------- --------------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market (XLON)
---------------------------------------- --------------------------------------------
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
The information set out below is provided in accordance with the
requirements of Article 19(3) of the EU Market Abuse Regulation No
596/2014.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Ewa Flynn
------------------------------------------ -------------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------------------
a) Position / status Chief Financial Officer (PDMR)
------------------------------------------ -------------------------------------------
b) Initial notification Initial notification
/ Amendment
------------------------------------------ -------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------------------
a) Name ImmuPharma PLC
------------------------------------------ -------------------------------------------
b) LEI 213800VZKGHXC7VUS895
------------------------------------------ -------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
---------------------------------------------------------------------------------------
a) Description of the Ordinary Shares of 10p each
financial instrument
, type of instrument
ISIN: GB0033711010
Identification code
------------------------------------------ -------------------------------------------
b) Nature of the transaction On-market purchase
------------------------------------------ -------------------------------------------
c) Price(s) and volume(s) Price Volume
------------------------------------------ ---------------------- -------------------
7.892p 30,000
----------------------------------------------- ---------------------- -------------------
d) Aggregated information
- Aggregated volume
- Price
------------------------------------------ -------------------------------------------
e) Date of the transaction 23 August 2021
------------------------------------------ -------------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market (XLON)
------------------------------------------ -------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHPIMMTMTMTBAB
(END) Dow Jones Newswires
August 24, 2021 06:07 ET (10:07 GMT)
Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
